(EMAILWIRE.COM, April 04, 2008 ) Denver, CO - LegalView.com, the most comprehensive resource for everything legal on the Web, recently updated its Singulair practice area with information on the potential for a Singulair recall (http://singulair.legalivew.com) after the U.S. Food and Drug Administration (FDA) began investing links of increased suicide risks among patients prescribed Singulair. Singulair is an oral medication prescribed to victims of asthma as well as those with severe allergy symptoms.

Merck & Co., makers of the drug, are currently working with the FDA to determine the risks of the Singulair side effects (http://singulair.legalview.com), which have been reported by patients and physicians to include mood changes, suicidal thoughts and behavior, and suicidal actions. The FDA recommends that individuals who are currently taking Singulair contact their physician immediately, and while a Singulair class action (http://singulair.legalview.com) lawsuit does not currently exist; it may be advisable for Singulair patients to contact an experienced pharmaceutical lawyer to discuss the Singulair warning (http://singulair.legalview.com).

The FDA investigation was spurred by reports of suicidal tendencies among nearly 11,000 patients of all ages who were enrolled in approximately 40 Singulair drug trials. Additionally, the FDA is reviewing mood and behavioral imbalances among patients of similar allergy prescription drugs as well to determine side effects of Singulair and similar drug types. However, individuals who are taking Singulair might consider contacting a pharmaceutical law firm to receive an attorney consultation on any possible Singulair lawsuit (http://singulair.legalview.com).

To learn more about this and additional controversial pharmaceutical drugs being investigated by the FDA, readers should visit LeglaView's other Unsafe Drugs information portals. Individuals will find a plentitude of information ranging from the controversy surrounding Vytorin to Chantix side effects to the risk of osteoporosis among Avandia patients.

Vytorin (http://vytorin.legalview.com) is a two part drug prescribed for the treatment of high cholesterol, which usually involves an elevation of lipids due to diet or lifestyle. An extensive study completed in mid-2006, and released in January 2008 has shown that taking Vytorin had no benefit on the buildup of artery plaque when compared with patients taking only Zocor, additionally, Vytorin is three times more expensive than the generic version of Zocor (simvastatin). For more information on this drug and the controversy surrounding this study, visit the LegalView Vytorin information portal.

Chantix is a smoking cessation aid that, similar to Singulair, has been linked to an increase in suicidal tendencies affecting nearly 400 individuals as well as having allegedly been linked to approximately 40 suicides. Chantix side effects can include suicidal behaviors and thoughts, depression and psychotic episodes (http://chantix.legalview.com). Individuals who are taking Chantix and have experienced these symptoms should contact a medical professional immediately and locate a pharmaceutical attorney for additional advice and consultation.

LegalView also continues to report news on the Avandia risks (http://avandia.legalview.com) that can include an increased risk of heart disease as well as advanced cases of osteoporosis and bone fractures among patients taking the drug. To learn more visit http://avandia.legalview.com/.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at http://www.LegalView.com/.

Contact Information:
LegalView
Katie Kelley
Tel: 720-771-3246
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.